Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antidepressant may help in dementia, researchers find
Researchers also found that the antidepressant was associated with “significantly lower” adverse side effects. The study, funded by the National Institutes of Health and published in the online
Researchers also found that the antidepressant was associated with “significantly lower” adverse side effects. The study, funded by the National Institutes of Health and published in the online
The Phase IIb study is a randomized, double-blind, placebo-controlled study comparing 200mg 3x/day and 400mg 3x/day of bicifadine versus placebo, with a 1:1:1 randomization between the three arms,
Dr Jaap Goudsmit, Crucell's chief scientific officer, said: “Crucell's vaccine technologies, PER.C6 and AdVac, are increasingly used by the vaccine industry to develop important novel vaccines for infectious
Teva said that the court has issued an order temporarily enjoining the company from further sales of generic Famciclovir tablets, AB-rated to Novartis’s Famvir tablets. The injunction will
The first patient has been enrolled and dosed in the study. The trial is a randomized, double-blind and placebo-controlled dose-ranging trial to evaluate the efficacy of ABT-894 in
The agency’s observations led to the issuance of a warning letter on May 24, 2007. The UK facility is the bulk manufacturing site for FluMist (influenza virus vaccine
The CD20 antibodies were incubated with tumor cells and analyzed using spinning disk confocal fluorescent microscopy. Genmab says that this technology allows imaging of the effects on target
The company enrolled 22 patients with advanced, previously treated solid tumors in the study before closing enrollment in July 2007. The results concern 19 patients evaluated for safety
INGN 225 is an immunotherapy using a patient's own cells to stimulate an anti-tumor immune response to fight cancer. The immunotherapeutic targets a molecular abnormality found in over
Under the terms of the agreement, the costs of the collaboration projects will be borne 60% by Aradigm and 40% by CyDex, with third-party licensing and sales revenues